Nutex Health (NUTX)
Market Price (9/24/2026): $202.0 | Market Cap: $1.4 BilSector: Health Care | Industry: Health Care Facilities
Nutex Health (NUTX)
Market Price (9/24/2026): $202.0Market Cap: $1.4 BilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 19%, Dividend Yield is 6.1%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 15%, FCF Yield is 20% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 43% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 32% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Diabetes Management, Show more. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17% | Stock price has recently run up significantly6M Rtn6 month market price return is 101% Weak revenue growthRev Chg QQuarterly Revenue Change % is -14% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 117% Key risksNUTX key risks include [1] a heavy dependence on volatile out-of-network arbitration revenue, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 19%, Dividend Yield is 6.1%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 15%, FCF Yield is 20% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 43% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 32% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Diabetes Management, Show more. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 101% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -14% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 117% |
| Key risksNUTX key risks include [1] a heavy dependence on volatile out-of-network arbitration revenue, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nutex Health (NUTX) stock has gained about 55% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q2 2026 Financial Rebound: Nutex Health reported a significant turnaround in its fiscal Q2 2026 results (ended June 30, 2026), posting diluted earnings per share (EPS) of $9.38, substantially exceeding analysts' consensus estimates of $4.95 by $4.43. The company swung to a net income attributable to Nutex Health of $65.8 million, a marked improvement from a $17.7 million loss in fiscal Q2 2025. Furthermore, EBITDA attributable to Nutex Health reached $94.1 million, compared to a negative $0.5 million in the prior year's comparable quarter.
2. Robust First Half of Fiscal 2026 Profitability and Cash Flow: For the first six months of fiscal 2026 (ended June 30, 2026), Nutex Health achieved a net income attributable to the company of $112.6 million, or diluted EPS of $15.87, representing a 3100% increase compared to $3.5 million, or diluted EPS of $0.55, in the same period of fiscal 2025. This strong profitability was supported by a significant rise in net cash provided by operating activities, which increased to $109.7 million for the first half of fiscal 2026 from $78.2 million in the corresponding period of fiscal 2025.
Show more
Nutex Health (NUTX) stock has gained about 55% since 5/31/2026 because of the following key factors:
1. Exceptional Fiscal Q2 2026 Financial Rebound: Nutex Health reported a significant turnaround in its fiscal Q2 2026 results (ended June 30, 2026), posting diluted earnings per share (EPS) of $9.38, substantially exceeding analysts' consensus estimates of $4.95 by $4.43. The company swung to a net income attributable to Nutex Health of $65.8 million, a marked improvement from a $17.7 million loss in fiscal Q2 2025. Furthermore, EBITDA attributable to Nutex Health reached $94.1 million, compared to a negative $0.5 million in the prior year's comparable quarter.
2. Robust First Half of Fiscal 2026 Profitability and Cash Flow: For the first six months of fiscal 2026 (ended June 30, 2026), Nutex Health achieved a net income attributable to the company of $112.6 million, or diluted EPS of $15.87, representing a 3100% increase compared to $3.5 million, or diluted EPS of $0.55, in the same period of fiscal 2025. This strong profitability was supported by a significant rise in net cash provided by operating activities, which increased to $109.7 million for the first half of fiscal 2026 from $78.2 million in the corresponding period of fiscal 2025.
3. Positive Analyst Sentiment and Upgraded Price Targets: Following the strong financial performance, brokerage firms maintained a bullish outlook on Nutex Health, with a consensus "Buy" rating from multiple analysts. The average 12-month price target among analysts covering the stock is approximately $317.50. Notably, some analysts, such as B. Riley Financial and Lake Street Capital, increased their price targets to $325.00 (from $290.00) and $310.00 (from $235.00), respectively.
4. Enhanced Visibility and Operational Growth through Nasdaq Texas Dual Listing: Nutex Health secured approval to dual-list its common stock on Nasdaq Texas, with trading commencing around September 23, 2026. This strategic move aims to broaden the company's visibility among regional institutional investors while sustaining its existing national and international presence on the Nasdaq Global Market. Operationally, the company continues its expansion, with hospital division visits increasing by 9.6% year-over-year in fiscal Q2 2026, and plans to open 3 to 5 new facilities annually, complementing its current network of 28 facilities across 12 states.
Show less
Stock Movement Drivers
Fundamental Drivers
The 56.3% change in NUTX stock from 5/31/2026 to 9/23/2026 was primarily driven by a 94.0% change in the company's Net Income Margin (%).| (LTM values as of) | 5312026 | 9232026 | Change |
|---|---|---|---|
| Stock Price ($) | 129.11 | 201.86 | 56.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 880 | 847 | -3.8% |
| Net Income Margin (%) | 11.0% | 21.2% | 94.0% |
| P/E Multiple | 9.4 | 7.7 | -17.7% |
| Shares Outstanding (Mil) | 7 | 7 | 1.7% |
| Cumulative Contribution | 56.3% |
Market Drivers
5/31/2026 to 9/23/2026| Return | Correlation | |
|---|---|---|
| NUTX | 56.3% | |
| Market (SPY) | 1.8% | 25.6% |
| Sector (XLV) | 13.4% | 24.1% |
Fundamental Drivers
The 82.7% change in NUTX stock from 2/28/2026 to 9/23/2026 was primarily driven by a 72.9% change in the company's Net Income Margin (%).| (LTM values as of) | 2282026 | 9232026 | Change |
|---|---|---|---|
| Stock Price ($) | 110.46 | 201.86 | 82.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 981 | 847 | -13.7% |
| Net Income Margin (%) | 12.3% | 21.2% | 72.9% |
| P/E Multiple | 6.1 | 7.7 | 25.6% |
| Shares Outstanding (Mil) | 7 | 7 | -2.5% |
| Cumulative Contribution | 82.7% |
Market Drivers
2/28/2026 to 9/23/2026| Return | Correlation | |
|---|---|---|
| NUTX | 82.7% | |
| Market (SPY) | 12.5% | 29.9% |
| Sector (XLV) | 6.3% | 27.2% |
Fundamental Drivers
The 140.9% change in NUTX stock from 8/31/2025 to 9/23/2026 was primarily driven by a 80.0% change in the company's Net Income Margin (%).| (LTM values as of) | 8312025 | 9232026 | Change |
|---|---|---|---|
| Stock Price ($) | 83.79 | 201.86 | 140.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 624 | 847 | 35.6% |
| Net Income Margin (%) | 11.8% | 21.2% | 80.0% |
| P/E Multiple | 6.4 | 7.7 | 19.6% |
| Shares Outstanding (Mil) | 6 | 7 | -17.5% |
| Cumulative Contribution | 140.9% |
Market Drivers
8/31/2025 to 9/23/2026| Return | Correlation | |
|---|---|---|
| NUTX | 140.9% | |
| Market (SPY) | 20.3% | 28.1% |
| Sector (XLV) | 25.0% | 11.4% |
Fundamental Drivers
The 386.0% change in NUTX stock from 8/31/2023 to 9/23/2026 was primarily driven by a 329.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9232026 | Change |
|---|---|---|---|
| Stock Price ($) | 41.53 | 201.86 | 386.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 197 | 847 | 329.0% |
| P/S Multiple | 0.9 | 1.6 | 78.6% |
| Shares Outstanding (Mil) | 4 | 7 | -36.6% |
| Cumulative Contribution | 386.0% |
Market Drivers
8/31/2023 to 9/23/2026| Return | Correlation | |
|---|---|---|
| NUTX | 386.0% | |
| Market (SPY) | 77.0% | 21.3% |
| Sector (XLV) | 33.2% | 7.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NUTX Return | 0% | 35% | -91% | 17% | 419% | 27% | -1% |
| Peers Return | 24% | -18% | 11% | -1% | 19% | 79% | 139% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 107% |
Monthly Win Rates [3] | |||||||
| NUTX Win Rate | 0% | 42% | 17% | 50% | 58% | 56% | |
| Peers Win Rate | 59% | 50% | 57% | 52% | 58% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| NUTX Max Drawdown | 0% | -99% | -91% | -88% | -54% | -53% | |
| Peers Max Drawdown | -20% | -47% | -36% | -40% | -35% | -41% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PRVA, AGL, THC, HCA, UHS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/23/2026 (YTD)
How Low Can It Go
| Event | NUTX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -36.5% | -18.8% |
| % Gain to Breakeven | 57.4% | 23.1% |
| Time to Breakeven | 22 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -54.2% | -9.5% |
| % Gain to Breakeven | 118.3% | 10.5% |
| Time to Breakeven | 475 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -69.3% | -6.7% |
| % Gain to Breakeven | 225.6% | 7.1% |
| Time to Breakeven | 1091 days | 31 days |
In The Past
Nutex Health's stock fell -36.5% during the 2025 US Tariff Shock. Such a loss loss requires a 57.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NUTX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -36.5% | -18.8% |
| % Gain to Breakeven | 57.4% | 23.1% |
| Time to Breakeven | 22 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -54.2% | -9.5% |
| % Gain to Breakeven | 118.3% | 10.5% |
| Time to Breakeven | 475 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -69.3% | -6.7% |
| % Gain to Breakeven | 225.6% | 7.1% |
| Time to Breakeven | 1091 days | 31 days |
In The Past
Nutex Health's stock fell -36.5% during the 2025 US Tariff Shock. Such a loss loss requires a 57.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Nutex Health (NUTX)
Nutex Health, Inc. (NUTX) is a technology-enabled healthcare services company that operates through two distinct but complementary divisions. The company's business model integrates direct patient care with advanced population health management solutions, aiming to enhance healthcare delivery across various settings.
The Hospital division is responsible for implementing and operating healthcare facilities, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division directly serves patients in need of acute or specialized medical care, currently owning and operating 21 facilities across 8 states. Through these facilities, Nutex Health provides a range of medical services, making direct patient care a core offering.
Complementing its direct care services, the Population Health Management division focuses on owning and operating provider networks, such as independent physician associations. This division provides management, administrative, and support services to its affiliated hospitals and physician groups through its management services organizations. It also utilizes a proprietary cloud-based technology platform to aggregate patient and provider data, enabling a holistic view to facilitate better care coordination and delivery for its network participants and their patients.
AI Analysis | Feedback
- Imagine a company like **Optum** (UnitedHealth Group's health services arm) that not only provides tech-enabled healthcare management services but also owns and operates its own network of specialized hospitals.
- Think of it as a specialized version of **HCA Healthcare** (a large hospital operator) that has also built a sophisticated data analytics and management platform for healthcare, similar to a sector-specific **Palantir** for patient and provider networks.
AI Analysis | Feedback
- Healthcare Facility Operation: Provides direct patient care through the operation of micro-hospitals, specialty hospitals, and hospital outpatient departments.
- Provider Network Management: Manages and operates networks of healthcare providers, such as independent physician associations.
- Healthcare Administrative Services: Offers management, administrative, and support services to affiliated hospitals and physician groups.
- Population Health Technology Platform: Delivers a cloud-based proprietary technology platform for aggregating health data to support holistic patient care and provider management.
AI Analysis | Feedback
Nutex Health operates a Hospital division that owns and operates 21 healthcare facilities, including micro-hospitals, specialty hospitals, and hospital outpatient departments. Its Population Health Management division owns and operates provider networks, such as independent physician associations, and provides management, administrative, and support services to its affiliated hospitals and physician groups. In both divisions, the ultimate recipients of care and primary customers are individuals.
The company serves the following categories of individual customers:
- Patients seeking acute and specialty care: Individuals who visit Nutex's micro-hospitals and specialty hospitals for urgent medical needs, specific treatments, or surgical procedures.
- Patients utilizing outpatient services: Individuals accessing services at Nutex's hospital outpatient departments, which may include diagnostic testing, therapy, minor procedures, and follow-up care.
- Patients managed through provider networks: Individuals who receive primary care and coordinated health management services from the physicians and providers within Nutex's independent physician associations and broader provider networks.
AI Analysis | Feedback
AI Analysis | Feedback
Thomas T. Vo, M.D., MBA Chief Executive Officer & Chairman of the Board
Dr. Vo was appointed CEO on April 1, 2022, and also serves as the Chairman of the Board. He is a founder and executive officer of Nutex affiliates since 2010. Prior to his role at Nutex Health, he worked as an emergency medicine physician in Houston for over 20 years and was instrumental in the co-leading of over 40 freestanding emergency departments and micro-hospitals since 2008. He was a founder and original partner at Neighbors Emergency Center between 2008 and 2011. He founded Nutex Health. In 2020, Dr. Vo received the prestigious EY Entrepreneur Of The Year® award.
Jon Bates, MBA, CPA Chief Financial Officer
Mr. Bates was appointed Chief Financial Officer effective on or about June 30, 2022. He is an experienced finance leader with a CPA and MBA. Since 2006, he served as Vice President of Accounting and Corporate Controller at U.S. Physical Therapy, Inc. (NYSE: USPH), one of the largest publicly traded operators of outpatient physical therapy clinics. In this role, he was responsible for monitoring closing processes for over 600 locations with approximately $500 million in annual revenues and managed merger and acquisition tasks from valuation/modeling to due diligence and integration post-acquisition. His prior roles include Chief Financial Officer and Chief Accounting Officer at Commerciant, L.P., Chief Accounting Officer and Corporate Controller at National Alarm Technologies LLC, Assistant Corporate Controller at American Residential Services, Inc., and Senior Auditor at Arthur Andersen LLP.
Warren Hosseinion, M.D. President
Dr. Hosseinion serves as the President and a Director of Nutex Health. He previously held the positions of Chief Executive Officer and Chairman of the Board of Clinigence Holdings, Inc. He is also a Co-Founder of Apollo Medical Holdings, Inc. (NASDAQ: AMEH), where he served as a member of the Board of Directors from July 2008 until March 2019, Chief Executive Officer from July 2008 to December 2017, and Co-Chief Executive Officer from December 2017 to March 2019. Additionally, Dr. Hosseinion co-founded ApolloMed Hospitalists in 2001.
Wesley Bamburg, FACHE Chief Operating Officer
Mr. Bamburg was appointed Chief Operating Officer effective October 13, 2025. He brings 20 years of Fortune 500 experience in healthcare operations, business development, integrated network management, and physician relations. Before joining Nutex Health, he served as Chief Operating Officer for HCA Houston Healthcare North Cypress since July 2024 and as Chief Operating Officer at HCA Houston Healthcare Medical Center from 2019 to 2024. Mr. Bamburg began his career with HCA Healthcare in 2013 as the Gulf Coast Division’s Vice President of Payor Contracting & Alignment.
Michael Chang, M.D. Chief Medical Officer
Dr. Chang serves as the Chief Medical Officer of Nutex Health.
AI Analysis | Feedback
The key risks to Nutex Health's business include:
-
Regulatory and Reimbursement Environment
Nutex Health's operations, particularly its hospital division which includes micro-hospitals and specialty hospitals, are highly susceptible to changes in healthcare regulations and reimbursement policies. The healthcare industry is subject to extensive and evolving federal, state, and local laws and regulations concerning licensure, accreditation, privacy, and billing practices. Changes in government healthcare programs, such as Medicare and Medicaid, or private insurer reimbursement rates, could significantly impact the company's revenue and operational viability, especially as micro-hospitals have faced scrutiny regarding their cost-effectiveness and necessity.
-
Intense Competition and Operational Challenges in Healthcare Delivery
Operating 21 facilities across 8 states means Nutex Health faces significant competition from established, larger hospital systems, other specialty providers, and outpatient clinics. The healthcare services market is highly competitive, and the company must continuously attract patients and qualified medical professionals. Furthermore, the ownership and operation of healthcare facilities are capital-intensive, requiring substantial ongoing investment in equipment, technology, and staffing, which can be challenging in an environment of rising costs and potential labor shortages.
-
Technology Dependence and Data Security Risks
The Population Health Management division heavily relies on its cloud-based proprietary technology platform to aggregate data and deliver care. This dependence introduces significant risks related to cybersecurity breaches, system failures, and the protection of sensitive patient data. A breach could lead to severe financial penalties under regulations like HIPAA, reputational damage, and loss of trust from patients and providers. Additionally, continuous investment is required to maintain, update, and secure this technology platform against evolving threats and ensure its effectiveness in supporting care delivery and management services.
AI Analysis | Feedback
The increasing sophistication and adoption of virtual-first healthcare models pose a clear emerging threat. As advanced telemedicine, remote diagnostics, and AI-driven health platforms continue to evolve, they could significantly reduce the necessity for physical visits to Nutex Health's micro-hospitals, specialty hospitals, and hospital outpatient departments, thereby eroding the demand for its facility-based services.
Another clear emerging threat is the aggressive expansion of major Electronic Health Record (EHR) vendors and large health insurance payers into comprehensive population health management solutions. As these dominant industry players integrate increasingly robust population health capabilities directly into their core systems and incentivize their use across provider networks, Nutex Health's independent proprietary technology platform could face substantial challenges in market adoption and maintaining competitive relevance against integrated, bundled, or mandated solutions from larger ecosystems.
AI Analysis | Feedback
The addressable markets for Nutex Health's main products and services in the U.S. are substantial across its two divisions:
Hospital Division
- Micro-Hospitals: The micro-hospitals market in the U.S. was valued at approximately USD 245.82 billion in 2022 and is projected to grow to about USD 455 billion by 2030.
- Specialty Hospitals: The market size for Specialty Hospitals in the U.S. was approximately USD 66.5 billion in 2024 and is expected to reach USD 66.8 billion in 2025.
- Hospital Outpatient Departments: The U.S. hospital services market size is valued at USD 2.64 trillion in 2025, with outpatient services accounting for the largest share at 52% in the same year. This indicates an addressable market of approximately USD 1.37 trillion for hospital outpatient services in the U.S. in 2025.
Population Health Management Division
- Population Health Management Services: The United States population health management market size was valued at approximately USD 25.6 billion in 2025 and is estimated to reach USD 124.9 billion by 2034.
AI Analysis | Feedback
Nutex Health (NASDAQ: NUTX) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and operational strengths across its Hospital and Population Health Management divisions.
Here are key expected drivers of future revenue growth:
- Expansion of Hospital Division through New Facility Development: Nutex Health plans to continue expanding its hospital network by developing new facilities. The company successfully opened three new hospitals in 2025 and early 2026, increasing its footprint to 27 facilities across 12 states. Management has indicated plans for further "de novo hospital development" as a core growth strategy.
- Increased Patient Volumes at Existing Facilities: The company anticipates growth from higher patient volumes across its current hospital portfolio. In 2025, hospital division visits increased by 11.8% year-over-year to 188,279. The CEO has specifically highlighted growth in both emergency room visits and inpatient admissions, indicating heightened demand and improved operational efficiency at existing sites.
- Continued Success in Independent Dispute Resolution (IDR) and Higher Acuity Claims: A significant portion of Nutex Health's hospital revenue in 2025 (approximately 63% or $527.8 million) was attributed to higher acuity claims and successful outcomes in the Independent Dispute Resolution process. The company reports prevailing in over 85% of IDR determinations, with a high collection rate. Nutex Health intends to continue its strategic participation in arbitration processes under the No Surprises Act to enhance revenue. Furthermore, patient revenue per visit has shown significant improvements due to enhanced negotiated rates, higher case acuity, and increased overnight stays.
- Expansion of Population Health Management Division with New Independent Physician Associations (IPAs): Nutex Health's Population Health Management division is focused on expanding its network of independent physician associations (IPAs). The company aims to launch one to three new IPAs annually, primarily in areas surrounding its existing micro-hospitals, to leverage synergies and broaden its risk-bearing physician network.
AI Analysis | Feedback
Share Repurchases
- Nutex Health authorized a stock repurchase program of up to $25.0 million on August 14, 2025, with the intent to increase shareholder value and offset dilution.
- This initial $25.0 million share repurchase program was extended through March 31, 2026.
- On March 5, 2026, the Board of Directors authorized a second stock repurchase program, also for up to $25.0 million of the company's common stock, to be executed over the subsequent six months.
Share Issuance
- On April 1, 2022, the merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc. resulted in the issuance of an aggregate of 592,791,712 shares of common stock to the equity holders of Nutex Health Holdco LLC.
- The company reported significant stock-based compensation expenses, totaling $117.0 million for 2025, compared to $16.6 million for 2024, which largely included one-time obligations for earn-out shares related to under-construction and ramping hospitals.
- A $99.31 million shelf registration for 1,100,000 common shares was authorized, tied to an ESOP-related offering, indicating potential future share issuance.
Inbound Investments
- The formation of Nutex Health Inc. on April 1, 2022, through the merger of Nutex Health Holdco LLC and Clinigence Holdings, Inc., represented a significant restructuring that integrated the assets and equity of Nutex Health Holdco LLC into the public entity.
Outbound Investments
- In 2022, payments for acquisitions of businesses, net of cash acquired, amounted to $704 thousand.
- Cash related to asset acquisitions totaled $4.312 million in 2025.
Capital Expenditures
- In Q4 2025, Nutex Health Inc. invested $1.4 million in capital expenditures, marking a 366.6% increase from the prior quarter.
- A primary focus of capital allocation is the expansion of the company's hospital division, involving the implementation and operation of new micro-hospitals, specialty hospitals, and hospital outpatient departments.
- The company expanded its operations to 27 hospital facilities across 12 states by the end of 2025, up from 21 facilities in 8 states previously, demonstrating ongoing capital deployment for network growth.
Peer Outperformance in Health Care Facilities
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 11.6% | 44.3% | 89.1% | CAH 382% · MCK 344% · COR 169% |
| Managed Health Care | 8 | 33.1% | -7.9% | -0.7% | OSCR 80% · HQY 37% · ELV 12% |
| Health Care Services | 20 | 18.1% | 34.7% | -2.4% | HIMS 250% · RDNT 151% · DGX 68% |
| Health Care Facilities ← | 24 | 5.4% | 11.5% | -4.7% | NHC 271% · THC 259% · ENSG 135% |
| Health Care Equipment | 50 | -1.9% | -1.3% | -20.7% | POCI 11788% · UFPT 362% · GKOS 203% |
| Health Care Supplies | 12 | 20.3% | -6.4% | -38.9% | LNTH 271% · HAE 54% · MMSI 20% |
| Pharmaceuticals | 63 | -9.2% | 9.6% | -40.4% | LQDA 2252% · INDV 1097% · ETON 1010% |
| Life Sciences Tools & Services | 113 | 4.7% | -9.1% | -68.4% | SNWV 1820% · NTRA 231% · MEDP 211% |
| Health Care Technology | 21 | -26.8% | -50.0% | -78.6% | SPOK 71% · HSTM 1% · VEEV -10% |
| Biotechnology | 378 | -4.0% | -21.9% | -79.0% | CELZ 1291% · DNTH 1151% · ELVN 997% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 191.62 |
| Mkt Cap | 6.6 |
| Rev LTM | 12,017 |
| Op Inc LTM | 1,211 |
| FCF LTM | 542 |
| FCF 3Y Avg | 486 |
| CFO LTM | 1,040 |
| CFO 3Y Avg | 962 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.4% |
| Rev Chg 3Y Avg | 12.9% |
| Rev Chg Q | 8.5% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Inc Chg LTM | 31.9% |
| Op Inc Chg 3Y Avg | 23.7% |
| Op Mgn LTM | 13.4% |
| Op Mgn 3Y Avg | 12.9% |
| QoQ Delta Op Mgn LTM | 1.1% |
| CFO/Rev LTM | 12.1% |
| CFO/Rev 3Y Avg | 12.5% |
| FCF/Rev LTM | 6.6% |
| FCF/Rev 3Y Avg | 6.7% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Hospital division | 844 | 449 | 218 | 199 | 332 |
| Population health management division | 31 | 31 | 30 | 21 | 0 |
| Real estate division | 2 | 2 | -1 | 0 | |
| Revenue from inter-segment activities (expense) | -2 | -2 | 1 | -0 | |
| Total | 875 | 480 | 248 | 219 | 332 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Hospital division | 444 | 196 | 36 | 15 | 179 |
| Population health management division | 1 | 1 | -2 | 0 | 0 |
| Real estate division | -0 | -1 | -0 | -0 | |
| Corporate and other costs | -169 | -66 | -67 | -422 | |
| Total | 276 | 131 | -32 | -407 | 179 |
| $ Mil | 2020 |
|---|---|
| Healthcare | 104 |
| Eliminations | -3 |
| Total | 101 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Hospital division | 851 | 608 | 279 | 314 | |
| Real estate division | 38 | 19 | 36 | 40 | 138 |
| Population health management division | 30 | 28 | 84 | 78 | |
| Eliminations | -152 | ||||
| Healthcare | 323 | ||||
| Total | 919 | 655 | 398 | 432 | 309 |
Price Behavior
| Market Price | $201.86 | |
| Market Cap ($ Bil) | 1.4 | |
| First Trading Date | 04/08/2013 | |
| Distance from 52W High | -7.1% | |
| 50 Days | 200 Days | |
| DMA Price | $180.81 | $145.32 |
| DMA Trend | up | up |
| Distance from DMA | 11.6% | 38.9% |
| 3M | 1YR | |
| Volatility | 80.4% | 92.1% |
| Downside Capture | 54.58 | 217.52 |
| Upside Capture | 196.63 | 257.72 |
| Correlation (SPY) | 21.3% | 27.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.80 | 2.92 | 1.72 | 1.86 | 2.13 | 1.51 |
| Up Beta | 0.87 | 2.39 | 2.58 | 1.68 | 1.25 | 1.56 |
| Down Beta | 11.00 | 4.17 | 1.83 | 2.27 | 1.84 | 1.36 |
| Up Capture | 496% | 288% | 270% | 301% | 758% | 667% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 12 | 19 | 33 | 69 | 134 | 377 |
| Down Capture | 94% | 305% | 59% | 131% | 163% | 108% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 9 | 23 | 31 | 58 | 117 | 368 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NUTX | |
|---|---|---|---|---|
| NUTX | 103.0% | 92.0% | 1.17 | - |
| Sector ETF (XLV) | 25.2% | 16.1% | 1.20 | 10.6% |
| Equity (SPY) | 16.2% | 13.0% | 0.88 | 27.5% |
| Gold (GLD) | 13.9% | 29.3% | 0.44 | 11.2% |
| Commodities (DBC) | 46.6% | 20.7% | 1.75 | -10.4% |
| Real Estate (VNQ) | 4.5% | 13.7% | 0.08 | 1.1% |
| Bitcoin (BTCUSD) | -23.2% | 44.8% | -0.46 | 17.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NUTX | |
|---|---|---|---|---|
| NUTX | -49.6% | 130.3% | 0.00 | - |
| Sector ETF (XLV) | 6.6% | 15.2% | 0.25 | 8.8% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 19.0% |
| Gold (GLD) | 18.6% | 18.8% | 0.80 | 5.6% |
| Commodities (DBC) | 10.5% | 19.5% | 0.41 | 0.1% |
| Real Estate (VNQ) | 0.8% | 18.9% | -0.06 | 14.6% |
| Bitcoin (BTCUSD) | 12.5% | 52.6% | 0.41 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NUTX | |
|---|---|---|---|---|
| NUTX | -39.2% | 144.6% | -0.01 | - |
| Sector ETF (XLV) | 10.8% | 16.7% | 0.53 | 11.3% |
| Equity (SPY) | 15.5% | 17.9% | 0.73 | 18.0% |
| Gold (GLD) | 12.1% | 16.4% | 0.60 | 7.6% |
| Commodities (DBC) | 8.5% | 18.1% | 0.38 | 1.1% |
| Real Estate (VNQ) | 4.9% | 20.7% | 0.20 | 16.1% |
| Bitcoin (BTCUSD) | 64.2% | 66.2% | 1.04 | 8.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/11/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 6.7% | 23.0% | 27.2% |
| 4/30/2026 | 17.1% | 12.9% | 7.4% |
| 3/5/2026 | -14.3% | -17.4% | -4.5% |
| 11/19/2025 | 26.9% | 0.5% | 60.0% |
| 8/21/2025 | -3.9% | -8.1% | 3.7% |
| 5/13/2025 | 26.1% | 40.7% | -0.8% |
| 11/7/2024 | 9.2% | 8.4% | 32.2% |
| 8/8/2024 | 27.8% | 65.3% | 163.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 9 | 7 |
| # Negative | 7 | 6 | 8 |
| Median Positive | 13.2% | 12.9% | 32.2% |
| Median Negative | -4.4% | -7.9% | -22.0% |
| Max Positive | 27.8% | 65.3% | 163.9% |
| Max Negative | -14.3% | -22.9% | -49.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | 6.7% | 23.0% | 27.2% |
| 4/30/2026 | 17.1% | 12.9% | 7.4% |
| 3/5/2026 | -14.3% | -17.4% | -4.5% |
| 11/19/2025 | 26.9% | 0.5% | 60.0% |
| 8/21/2025 | -3.9% | -8.1% | 3.7% |
| 5/13/2025 | 26.1% | 40.7% | -0.8% |
| 11/7/2024 | 9.2% | 8.4% | 32.2% |
| 8/8/2024 | 27.8% | 65.3% | 163.9% |
| 5/9/2024 | -4.4% | 11.6% | -7.9% |
| 11/9/2023 | -4.0% | -6.8% | -25.5% |
| 8/9/2023 | -4.4% | -4.3% | -22.9% |
| 5/15/2023 | -7.2% | -7.8% | -24.6% |
| 3/2/2023 | 1.6% | 9.4% | -21.1% |
| 11/22/2022 | 1.0% | 50.5% | 105.8% |
| 8/22/2022 | -4.7% | -22.9% | -49.7% |
| SUMMARY STATS | |||
| # Positive | 8 | 9 | 7 |
| # Negative | 7 | 6 | 8 |
| Median Positive | 13.2% | 12.9% | 32.2% |
| Median Negative | -4.4% | -7.9% | -22.0% |
| Max Positive | 27.8% | 65.3% | 163.9% |
| Max Negative | -14.3% | -22.9% | -49.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/19/2025 | 10-Q |
| 06/30/2025 | 11/18/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/03/2023 | 10-K |
| 09/30/2022 | 11/21/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/19/2025 | 10-Q |
| 06/30/2025 | 11/18/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/03/2023 | 10-K |
| 09/30/2022 | 11/21/2022 | 10-Q |
| 06/30/2022 | 08/22/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
Recent Forward Guidance
Updated 8/7/2026Latest: Q2 2026 Earnings Reported 8/6/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Contract Services Expenses Reduction | Reported | 0.25 | 0.28 | 0.3 | ||||
Prior: Q1 2026 Earnings Reported 4/30/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 New Hospital Openings | Reported | 3 | ||||||
| 2026 Annual Hospital Development Pace | Reported | 3 | 4 | 5 | ||||
Insider Activity
Updated 9/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Saunders, Scott J | Direct | Sell | 9182026 | 214.25 | 203 | 43,493 | 85,700 | Form | |
| 2 | Jaumot, Frank E | Direct | Buy | 3232026 | 93.56 | 150 | 14,033 | 14,033 | Form | |
| 3 | Hosseinion, Warren | President | Direct | Buy | 3232026 | 94.07 | 252 | 23,706 | 730,471 | Form |
| 4 | Spears, Kelvin | Direct | Buy | 3182026 | 94.46 | 10 | 945 | 3,035,661 | Form | |
| 5 | Montgomery, Pamela W | Chief Legal Officer-Healthcare | Direct | Buy | 3162026 | 88.87 | 79 | 7,021 | 245,103 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Saunders, Scott J | Direct | Sell | 9182026 | 214.25 | 203 | 43,493 | 85,700 | Form | |
| 2 | Jaumot, Frank E | Direct | Buy | 3232026 | 93.56 | 150 | 14,033 | 14,033 | Form | |
| 3 | Hosseinion, Warren | President | Direct | Buy | 3232026 | 94.07 | 252 | 23,706 | 730,471 | Form |
| 4 | Spears, Kelvin | Direct | Buy | 3182026 | 94.46 | 10 | 945 | 3,035,661 | Form | |
| 5 | Montgomery, Pamela W | Chief Legal Officer-Healthcare | Direct | Buy | 3162026 | 88.87 | 79 | 7,021 | 245,103 | Form |
| 6 | Bates, Jon Christian | Chief Financial Officer | Direct | Buy | 11282025 | 136.71 | 750 | 102,532 | 770,770 | Form |
Investor Activity (13F)
Updated Sep 24, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.